Actinogen Medical Widens Half-Year Loss as R&D Spending Rises

Actinogen Medical ( (AU:ACW) ) has provided an announcement.

Actinogen Medical reported a modest decline in revenue from ordinary activities for the half year to 31 December 2025, with income of $232,920, largely from interest on cash and short-term deposits. The company remains in an investment phase, posting a net loss attributable to members of $11.35 million, a 39% increase on the prior corresponding period, predominantly driven by higher research and development spending.

No dividends were paid or declared for the period, and the company signalled it does not intend to pay dividends in the near term, underscoring its focus on funding ongoing development programs. Actinogen did not enter into any acquisitions, joint ventures or foreign operations during the half, and its reviewed interim financial report was signed off by an independent auditor without qualification, providing shareholders with assurance on the integrity of the reported results.

The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical is an Australian biotechnology company focused on pharmaceutical research and development. The company’s activities centre on developing innovative therapies, with its primary expenditure directed toward R&D rather than revenue-generating commercial operations at this stage.

Average Trading Volume: 5,233,802

Technical Sentiment Signal: Hold

Current Market Cap: A$148.9M

See more insights into ACW stock on TipRanks’ Stock Analysis page.